CRUK

This page shows the latest CRUK news and features for those working in and with pharma, biotech and healthcare.

CRUK forges £30m ‘post-Brexit’ R&D alliance

CRUK forges £30m ‘ post-Brexit’ R&D alliance. Joins forces with organisations in Italy and Spain. ... Another £5m project led by CRUK’s Beatson Institute in Glasgow – ARCCelerate – will concentrate on finding new ways to deliver personalised

Latest news

London cancer hub launched by Cancer Research UK

A key project will be investigating the impact of cancer progression on the immune system, says CRUK. ... TME. “We believe that, in the future, the biotherapeutics field will transform cancer care, ”said CRUK’s chief clinician Prof Charles Swanton.
UK start-up Azeria emerges with £4m drug discovery pot for cancer

Boston and has been at the CRUK University of Cambridge lab since 2006, currently as a director of research.
Can a post-Brexit UK stay aligned with Europe on clinical research?

The UK government should continue to seek full regulatory alignment with the [CTR], ”says CRUK’s report. ... The ABPI also concurs with other points raised by CRUK, including the need for the UK government to focus on long-term funding initiatives or
Cancer Research UK to test Asterias’ lung cancer vaccine

Asterias isn’t the only biotech looking at telomerase as a cancer vaccine target, and this isn’t the first time that CRUK has backed such a product. ... Previous dendritic cell therapies have been made using patients’own cells, but according to
Merck forges closer ties with Cancer Research UK

Merck will have global clinical development and commercial rights to any candidates that look promising enough to take forward, with CRUK and the ICR in line for milestone payments if development ... It’s not the first time that Merck and CRUK have

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

AstraZeneca: building a new ‘open innovation’ pharma company

MRC scientists are welcome to work in the building and our oncology staff are working in the CRUK Institute.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Executive – Medical Communications: Salary TBC

Scientific Team Lead: Competitive Salary

Account Director – Global Healthcare PR: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Advertising: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Editorial Director – Medical Education: Neg

Associate Medical Director: Highly Competitive

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Associate Medical Director: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Director – Head of Public Affairs: Neg

Experienced Editor, London, Medical Communications: Competitive package

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Scientific Director: Highly Competitive Salary &Benefits

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Director: Negotiable

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Director - Digital: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Medical Writer (Remote Working): Competitive Salary Offered

Director Healthcare PR Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...